respiratory disease program (Charles River/AstraZeneca)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namerespiratory disease program (Charles River/AstraZeneca)
Drug Alias Namerespiratory disease program (BioFocus/AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRespiratory Tract Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBioFocus DPI
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBioFocus DPICharles River Laboratories International IncAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A